In recent years, pre-clinical investigations of TLR3-targeted therapy (Table 1) have focused on combination therapy of TLR3 agonism with other treatment modalities, including chemotherapy, tumor vaccines, and ICB. The gene discussed is TLR3; the disease is neoplasm.